$2.91
+0.02 (+0.69%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CABA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
Held by 9 tracked-famous managers (CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, Qube Research & Technologies Ltd, +4 more) · FINRA short interest 18.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusNCT06121297To evaluate incidence of adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: CABA-201, CABA-201 | Systemic Lupus Erythematosus, Lupus Nephritis | 28 | Dec 2029 | ≤ 1,230 d | 2026-08-18 |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia GravisNCT06359041To evaluate incidence and severity of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: CABA-201, CABA-201 | Generalized Myasthenia Gravis (gMG) | 24 | Sep 2029 | ≤ 1,138 d | 2026-08-13 |
| RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic SclerosisNCT06328777Phase 1/2: To evaluate incidence of adverse eventsNon-randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Biological: CABA-201, CABA-201 | Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases | 37 | Jul 2029 | ≤ 1,077 d | 2026-08-17 |
| A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)NCT04422912Adverse events, including Dose Limit ToxicityNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: DSG3-CAART, CABA-201 | Pemphigus Vulgaris | 40 | Jan 2029 | ≤ 896 d | 2026-05-29 |
| RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyNCT06154252Phase 1/2: Incidence and severity of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Biological: CABA-201 following preconditioning with fludarabine and cyclophosphamide | Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis | 74 | Jul 2028 | ≤ 712 d | 2026-07-23 |
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple SclerosisNCT07006805Primary (Part A: Dose Escalation) incidence and severity of adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio. | Biological: CABA-201 | Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis (MS) - Relapsing-remitting, Progressive Multiple Sclerosis | 0 | Sep 2028 | ≤ 773 d | 2026-06-25 |
| Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia GravisNCT05451212Adverse eventsOpen-label · Treatment | Phase 1 | Completed | Biological: MuSK-CAART | MuSK Myasthenia Gravis | 7 | 2025-07-24actual | — | 2025-11-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19